Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Third Telaprevir Pivotal Study Raises Bar For Competitors Another Notch

Executive Summary

Collective top-line data from the Phase III program testing Vertex Pharmaceuticals' protease inhibitor telaprevir in treatment-naïve and treatment-experienced hepatitis C patients set a high bar for competitors, particularly for Merck & Co.'s boceprevir, with which telaprevir is dueling to be the first approved specifically targeted antiviral therapy for hepatitis C (STAT-C).

You may also be interested in...

Advisory Panel To Consider Scope Of Indication For Merck's Hep C Drug Boceprevir

Agency asks about data on prior null responders and about anemia effects. Merck has proposed a safety monitoring program while avoiding REMS terminology.

Dual FDA Advisory Committee Reviews Shaping Up To Be A Showdown For Dueling Merck And Vertex Hepatitis C Drugs

Approval is widely assumed for both boceprevir and telaprevir, but there is still much to be discussed about the devilish details. Additional data coming out at European liver meeting should also be informative.

Vertex, Merck Face Education Challenge With Complex Hep C Regimens

With two direct acting antivirals now pending at FDA, the hepatitis C community is excited about adding efficacious new drugs to standard of care. But the regimens aren't as simple as that sounds; once the therapies are approved, the sponsors will have a considerable education effort on their hands, as physicians and patients work their way through the new HCV treatment calculus.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts